These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30942897)

  • 1. Real-World Data for Pediatric Pharmacometrics: Can We Upcycle Clinical Data for Research Use?
    Van Driest SL; Choi L
    Clin Pharmacol Ther; 2019 Jul; 106(1):84-86. PubMed ID: 30942897
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings of a Workshop: US Food and Drug Administration-International Society of Pharmacometrics Model-Informed Drug Development in Oncology.
    Bruno R; Jin JY; Maxfield K; Milligan L; Liu C; Wang Y; McKee AE; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):81-83. PubMed ID: 30951201
    [No Abstract]   [Full Text] [Related]  

  • 3. A Call for Objective Dose Selection to Increase Success in Pediatric Clinical Trials: A Perspective From NICHD and NIMH Program Staff.
    Giacoia G; Grabb MC; Pawlyk AC; Ren Z; Samedy-Bates L; Taylor-Zapata P
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S9-S12. PubMed ID: 34185908
    [No Abstract]   [Full Text] [Related]  

  • 4. Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children.
    Vinks AA; Barrett JS
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S52-S59. PubMed ID: 34185897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in Drug Development-Pediatric Dose Selection: Workshop Summary.
    Wang J; van den Anker JN; Burckart GJ
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S13-S21. PubMed ID: 34185909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020.
    Green FG; Park K; Burckart GJ
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S28-S35. PubMed ID: 34185898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Status Toward the Implementation of Precision Dosing in Children.
    Barrett JS; Barrett RF; Vinks AA
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S36-S51. PubMed ID: 34185896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The European Medicines Agency Experience With Pediatric Dose Selection.
    Manolis E; Musuamba FT; Karlsson KE
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S22-S27. PubMed ID: 34185894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal and Pediatric Dose Selection: Quo Vadis?
    Burckart GJ; van den Anker JN
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S7-S8. PubMed ID: 34185900
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-World Data: An Unrealized Opportunity in Global Health?
    Barrett JS; Heaton PM
    Clin Pharmacol Ther; 2019 Jul; 106(1):57-59. PubMed ID: 31188467
    [No Abstract]   [Full Text] [Related]  

  • 11. Small But Mighty: The Use of Real-World Evidence to Inform Precision Medicine.
    Miksad RA; Samant MK; Sarkar S; Abernethy AP
    Clin Pharmacol Ther; 2019 Jul; 106(1):87-90. PubMed ID: 31112289
    [No Abstract]   [Full Text] [Related]  

  • 12. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?
    Ren Z; Zajicek A
    Semin Perinatol; 2015 Nov; 39(7):530-1. PubMed ID: 26455383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of medications use in pregnancy.
    Ayad M; Costantine MM
    Semin Perinatol; 2015 Nov; 39(7):508-11. PubMed ID: 26358804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying potential prescription drug product hopping.
    Gowda V; Beall RF; Kesselheim AS; Sarpatwari A
    Nat Biotechnol; 2021 Apr; 39(4):414-417. PubMed ID: 33846649
    [No Abstract]   [Full Text] [Related]  

  • 15. The US Food and Drug Administration's Model-Informed Drug Development Paired Meeting Pilot Program: Early Experience and Impact.
    Madabushi R; Benjamin JM; Grewal R; Pacanowski MA; Strauss DG; Wang Y; Zhu H; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):74-78. PubMed ID: 31081932
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug Safety in Labeling for Pediatric Drug Development and Dose Selection in Submissions to the US Food and Drug Administration.
    Kim C; Park K; McMahon AW; Green FG; Green DJ; Burckart GJ
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S133-S140. PubMed ID: 34185899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial/ethnic differences in drug disposition and response: review of recently approved drugs.
    Ramamoorthy A; Pacanowski MA; Bull J; Zhang L
    Clin Pharmacol Ther; 2015 Mar; 97(3):263-73. PubMed ID: 25669658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
    Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
    JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Common errors in pharmacotherapy of patients with chronic kidney disease].
    Maus S; Keller F
    MMW Fortschr Med; 2011 Apr; 153(16):39-42. PubMed ID: 22329322
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.